Literature DB >> 15160288

Influence of telomerase activity on bone and soft tissue tumors.

Norifumi Umehara1, Toshifumi Ozaki, Shinsuke Sugihara, Toshiyuki Kunisada, Yuki Morimoto, Akira Kawai, Keiichiro Nishida, Aki Yoshida, Takuro Murakami, Hajime Inoue.   

Abstract

PURPOSE: Telomeres consisting of a repeating nucleotide sequence (TTAGGG)n are shortened in normal somatic cells. Telomerase is an enzyme that elongates the telomere sequence and is detected in most human cancers and usually not in normal somatic cells. Little is known about telomerase activity in bone and soft tissue tumors. The aim of this study was to investigate the relationship between telomerase activity and clinical factors in bone and soft tissue tumors.
METHODS: Telomerase activity was measured using the modified telomeric repeat amplification protocol (TRAP) assay in 115 bone and soft tissue tumors obtained through open biopsy or resection.
RESULTS: Telomerase activity was detected in 10% of benign tumors and 44% of malignant tumors (p < 0.001). A higher incidence of telomerase activity was detected in high-grade tumors than in low-grade tumors (p = 0.002). The cumulative metastasis-free and overall survival in telomerase-positive patients was significantly worse than in telomerase-negative patients (p = 0.045 and p = 0.048).
CONCLUSION: Our study suggests that telomerase activity is associated with tumor aggressiveness and may be a useful parameter to predict the prognosis of patients with malignant bone and soft tissue tumors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15160288     DOI: 10.1007/s00432-004-0553-z

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  25 in total

1.  Telomere end-replication problem and cell aging.

Authors:  M Z Levy; R C Allsopp; A B Futcher; C W Greider; C B Harley
Journal:  J Mol Biol       Date:  1992-06-20       Impact factor: 5.469

2.  Telomerase activity in soft-tissue and bone sarcomas.

Authors:  K Aogi; A Woodman; V Urquidi; D C Mangham; D Tarin; S Goodison
Journal:  Clin Cancer Res       Date:  2000-12       Impact factor: 12.531

Review 3.  Telomerase: a promising marker of biological immortality of germ, stem, and cancer cells. A review.

Authors:  A K Meeker; D S Coffey
Journal:  Biochemistry (Mosc)       Date:  1997-11       Impact factor: 2.487

4.  High telomerase activity and high HTRT mRNA expression differentiate pure myxoid and myxoid/round-cell liposarcomas.

Authors:  R Schneider-Stock; V Jaeger; J Rys; J T Epplen; A Roessner
Journal:  Int J Cancer       Date:  2000-01-20       Impact factor: 7.396

Review 5.  Telomerase activity in human cancer.

Authors:  J W Shay; W E Wright
Journal:  Curr Opin Oncol       Date:  1996-01       Impact factor: 3.645

6.  Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia: comparison with adult acute myeloid leukemia.

Authors:  Srdan Verstovsek; Taghi Manshouri; Franklin O Smith; Francis J Giles; Jorge Cortes; Elihu Estey; Hagop Kantarjian; Michael Keating; Sima Jeha; Maher Albitar
Journal:  Cancer       Date:  2003-05-01       Impact factor: 6.860

Review 7.  Preclinical and clinical strategies for development of telomerase and telomere inhibitors.

Authors:  S Sharma; E Raymond; H Soda; D Sun; S G Hilsenbeck; A Sharma; E Izbicka; B Windle; D D Von Hoff
Journal:  Ann Oncol       Date:  1997-11       Impact factor: 32.976

8.  Telomerase activity and human telomerase reverse transcriptase mRNA expression are correlated with clinical aggressiveness in soft tissue tumors.

Authors:  Ryota Tomoda; Masashi Seto; Hideaki Tsumuki; Koji Iida; Takashi Yamazaki; Jun Sonoda; Akihiko Matsumine; Atsumasa Uchida
Journal:  Cancer       Date:  2002-09-01       Impact factor: 6.860

9.  Telomerase activity and oncogenesis in giant cell tumor of bone.

Authors:  H S Schwartz; S F Juliao; M F Sciadini; L K Miller; M G Butler
Journal:  Cancer       Date:  1995-03-01       Impact factor: 6.860

Review 10.  Telomerase: a target for cancer therapeutics.

Authors:  Jerry W Shay; Woodring E Wright
Journal:  Cancer Cell       Date:  2002-10       Impact factor: 31.743

View more
  4 in total

1.  Telomere dysfunction promotes metastasis in a TERC null mouse model of head and neck cancer.

Authors:  Bojana Bojovic; David L Crowe
Journal:  Mol Cancer Res       Date:  2011-05-18       Impact factor: 5.852

Review 2.  Understanding Keloid Pathobiology From a Quasi-Neoplastic Perspective: Less of a Scar and More of a Chronic Inflammatory Disease With Cancer-Like Tendencies.

Authors:  Silvian Tan; Nonhlanhla Khumalo; Ardeshir Bayat
Journal:  Front Immunol       Date:  2019-08-07       Impact factor: 7.561

Review 3.  Improving outcomes for older women with gynaecological malignancies.

Authors:  Lucy Dumas; Alistair Ring; John Butler; Tania Kalsi; Danielle Harari; Susana Banerjee
Journal:  Cancer Treat Rev       Date:  2016-08-29       Impact factor: 12.111

4.  Telomere length is a prognostic biomarker in elderly advanced ovarian cancer patients: a multicenter GINECO study.

Authors:  Claire Falandry; Béatrice Horard; Amandine Bruyas; Eric Legouffe; Jacques Cretin; Jérôme Meunier; Jérôme Alexandre; Valérie Delecroix; Michel Fabbro; Marie-Noëlle Certain; Raymonde Maraval-Gaget; Eric Pujade-Lauraine; Eric Gilson; Gilles Freyer
Journal:  Aging (Albany NY)       Date:  2015-12       Impact factor: 5.682

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.